Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.

Cancers (Basel) · 2021 · PMC8123716 · PMID 33926021

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

a strong trendp = 0.056so close (0.05 < p ≤ 0.1)

wild-type BCOR : 18.4 months (95%-CI: 16.7–21.4), HR of LOF compared to wt BCOR = 1.409 (95%-CI: 1.010–1.965), p = 0.044), and a strong trend for reduced median OS in a multivariable analysis (HR = 1.495 (95%-CI: 0.990–2.258), p = 0.056, Figure 4 C).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.